{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}],"title":"Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Do you think atezolizumab SC is convenient? The responses to this question could be: Yes; No; and Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","groups":[{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire.","id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"NUMBER","populationDescription":"Overall number analyzed included HCPs who completed Question 2 of the questionnaire.","reportingStatus":"POSTED","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)","title":"Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire","type":"SECONDARY","unitOfMeasure":"percentage of HCPs"}